Allergan India :: About Us

Careers |Sitemap |Contact Us |Global Offices

About Us
	Home

Pharma Category

	Dry eye
	Conjunctivitis
	Glaucoma

	91-80-2229-9125 91-80-2229-9130
	allergan@agnindia.com


	ABOUT US
Allergan India Allergan India Pvt Ltd., a joint venture between Allergan Inc., and Nicholas Piramal India Limited, commenced commercial operations in 1996. Allergan India is a specialty pharmaceutical company. It has emerged as the market leader in the fast growing ophthalmic category with the successful launches of a series of high technology solutions and drugs for diseases such as glaucoma, dry eye and various other eye-infections and inflammations. Allergan India is today the partner of choice for majority of the eye-specialists in the country. With sales of around Rs. 85 crores and a strong organization, Allergan India is poised to grow at a rapid pace.
	J/V Partners
Allergan Inc Allergan Inc (Headquarter: Irvine, California, USA) is a global specialty pharmaceutical company with sales revenue of over US$ 3 billion and operations in over 100 countries. It has one of the highest R&D investment ratios in the pharmaceutical industry and is the fastest growing company in the eye-care pharmaceutical category. Allergan’s neuromodulator product Botox® is accepted as the standard therapy for treatment of many neuromuscular disorders. Botox® Cosmetic was approved by USA FDA in April 2002. Today, Botox ® is Allergan’s largest product with sales revenue of over US$ 700 million.

Nicholas Piramal India Limited A part of the Piramal group -- one of the leading & well diversified business groups in India, NPIL with a turnover 2004-05 of 13 billion rupees, is the sixth biggest drug maker (by value) in the country & 4th in ORG prescription sales ranking. 12 % of its 2004-05 turnover came from Exports. NPIL has 6000 employs, 15 divisions, 200 + products & businesses include Formulations, Bulk, Diagnostics & Exports. [top]

BUSINESS OPERATIONS Allergan India is headquartered in Bangalore & has an all India Sales & Marketing presence with an employee strength of around 250. It has one of the largest reach in Ophthalmic industry with a contact network with around 10000 Ophthalmologists with whom company shares a special relationship & goodwill. Apart from bringing to India in world class products from its global portfolio and R&D pipeline, Allergan India have taken efforts to locally develop and introduce products recognizing some specific unmet needs of Indian market. Allergan India has manufacturing arrangements with NPIL to source its Eye care Pharmaceutical product range, In addition to its focus areas of Eye care pharmaceuticals, thus giving Allergan India a comprehensive Eye care portfolio. Allergan India has been pioneer in Academic & Scientific initiatives in disease management areas, which has been its contribution in encouraging better diagnosis & disease management. Allergan India office also guides operations in Sri Lanka, Bangladesh, Pakistan & Nepal.[top]

Pharmaceutical Products The ophthalmic pharmaceutical market is over Rs. 4361 million in size and the company is a strong market leader with a market share of 17.4 % (MAT 06-2007, ORG – IMS) leaving next competition at around 12.3 % AGN India has been market leader since 1999. Covers a large range of segments in Eye care with major brands as: Refresh Tears, Combigan, Lumigan, Alphagan, Restasis, Refresh Liquigel, Tears Plus, Pred Acetate, Exopred, Acular, Genticyn. Company has a dominant share position in Glaucoma, Dry Eye and Anti-inflammatory products with individual segment shares in the range of 35—45 %. Range currently includes 30 products, 10 of which sell more than 1.0 units/anum, individually. [top]

Leveraging the Joint Venture Allergan India Joint Venture is an excellent example of building on the strengths of both partners. Specific areas of synergy and leverage are: a) Manufacturing Allergan pharmaceutical products are made at NPILs state of the art facility in Pithampur. This has ensured that the Indian consumer gets products manufactured to the best international quality standards at Indian prices. b) Raw Material Sourcing Allergan has worked with NPIL to develop and source selected bulk drugs for their global requirements from India. Operations/sourcing commenced in 2002 & NPIL plant in Hyderabad now supplies 2 bulk drugs to Allergan Inc for its Global requirements. This has enabled cost reduction for Allergan and is a valuable financial opportunity for NPIL as well. c) R&D Collaboration The joint venture also uses the product development capability of Nicholas Piramal to develop new ophthalmic products for India and the Asia Pacific region. We have already launched 7 products through this effort and more are in the pipeline. This enables the company to meet localised needs better. d) Exports Efforts are to use India as a cost effective source for certain markets, especially, in the neighboring region. Ophthalmic products are being exported since 2002 to countries in Asia & Africa regions. [top]

© 2007 Allergan all rights reserved

Pharma | News | Careers | Feedback | Contact us | Employe e | Botox